Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As Emergent Partnership Dissolves, BARDA Looks To Revamp Post-COVID Pandemic Preparedness

Executive Summary

BARDA terminates CIADM contract in wake of vaccine cross-contamination incident, begins discussion with industry about next steps for rapid pandemic response capabilities.

You may also be interested in...



US Forming Industry Consortia To Prepare For Future Pandemics And Global Supply Chain Disruptions

HHS agencies look to build on COVID-19 experience by developing quicker public/private responses to pandemics and supply chain threats.

BARDA Lays Out Vision For Next Pandemic: Vaccines For The US Within 130 Days

Federal agency seeks dialogue with industry on how to enable surge capacity for pandemic vaccines without cutting back on other production.One key factor: workforce development.

What To Do When Last Pandemic’s Answer To The Next Pandemic Falters: Point Fingers

US congressional ‘coronavirus crisis’ panel explores Emergent BioSolutions COVID-19 vaccine launch failures while scoring points about private sector support.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS145210

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel